Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
This randomized phase III trial studies how well combination chemotherapy, bevacizumab,
and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA)
mismatch repair colorectal cancer that has spread to other places in the body. Drugs used in
chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such
as bevacizumab and atezolizumab, may help the body''s immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Giving combination
chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with
Lebanon,Nashua,St. Johnsbury, VT
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.